ABSTRACT
This case report details a rare case of contraceptive implant migration in a young woman. The migration was discovered three years post-insertion during a routine replacement visit. Despite the absence of pulmonary symptoms, a CT scan revealed the implant in the inferior lobe of the right lung. The patient was referred for further evaluation, but immediate surgical removal was deferred. This case report highlights the importance of healthcare providers recognising migration as a rare complication during implantation and suggests self-examination as a potential preventive strategy.
Subject(s)
Contraceptive Agents, Female , Drug Implants , Foreign-Body Migration , Tomography, X-Ray Computed , Humans , Female , Foreign-Body Migration/diagnostic imaging , Foreign-Body Migration/surgery , Drug Implants/adverse effects , Contraceptive Agents, Female/adverse effects , Contraceptive Agents, Female/administration & dosage , Lung/diagnostic imaging , Lung/surgery , Adult , Desogestrel/adverse effects , Desogestrel/administration & dosageABSTRACT
A 17-year-old previously healthy female developed posterior reversible encephalopathy syndrome 1 week after etonogestrel implantation. She had a previous etonogestrel implant removed 4 months prior after unrelenting abdominal pain and hyponatremia with a negative workup for other etiologies, including hypercoagulable disorders and malignancy. This second insertion and resulting hospitalization allowed for the diagnosis of acute intermittent porphyria (AIP) to be confirmed. Progesterone can induce enzymatic activity upstream of porphobilinogen deaminase, the enzyme implicated in AIP, resulting in build-up of toxic metabolites. AIP requires high clinical suspicion for diagnosis but should be considered when hormonal triggers lead to unexplained neurovisceral symptoms.
Subject(s)
Desogestrel , Porphyria, Acute Intermittent , Humans , Female , Porphyria, Acute Intermittent/diagnosis , Porphyria, Acute Intermittent/chemically induced , Adolescent , Desogestrel/adverse effects , Desogestrel/administration & dosage , Contraceptive Agents, Female/adverse effects , Contraceptive Agents, Female/administration & dosage , Drug Implants/adverse effectsABSTRACT
BACKGROUND: To report a case of cataract surgery in unintentional Ozurdex (Allergan, Inc., Irvine, California, USA) injection into the lens. CASE PRESENTATION: A 82-years old man reporting decreased visual acuity in his right eye came to our Ophthalmology service. Due to the clinical history, and on the basis of ophthalmoscopic and imaging examinations diabetic macular edema was diagnosed. Thus, intravitreal dexamethasone implant was scheduled and therefore performed. The following day Ozurdex appeared to be located into the lens. After careful evaluation and strict follow up examinations, due to the risks associated with the presence of the implant into the lens, phacoemulsification with Ozurdex removal and intraocular lens (IOL) implantation was scheduled and performed. CONCLUSIONS: In this case report we reported the surgical management of accidental into-the lens dexamethasone implant carefully taking into account the dexamethasone pharmacokinetic.
Subject(s)
Dexamethasone , Drug Implants , Glucocorticoids , Humans , Dexamethasone/administration & dosage , Male , Aged, 80 and over , Glucocorticoids/administration & dosage , Drug Implants/adverse effects , Lens, Crystalline/surgery , Macular Edema/drug therapy , Macular Edema/etiology , Macular Edema/diagnosis , Phacoemulsification , Lens Implantation, Intraocular/adverse effects , Visual Acuity , Intravitreal InjectionsABSTRACT
INTRODUCTION: Migration is a rare but serious complication of the etonogestrel contraceptive implant, and little is known about its extent. PURPOSE: To document and characterise cases of etonogestrel contraceptive implant migration in the scientific literature. METHODS: A systematic review of Medline, Embase and Global Health databases was carried out between January 2000 and January 2023 to identify articles presenting implant migrations. Narrative reviews, conference abstracts and articles not written in English or French were excluded. RESULTS: Forty-five articles, mostly published since 2016, were identified (eight case series and 37 case reports), for a total of 148 independent cases of migration: in pulmonary blood vessels (n = 74), in non-pulmonary blood vessels (n = 16) and extravascular (n = 58). Many patients are asymptomatic and migration is often an incidental finding. A non-palpable implant and symptoms related to implant location (intra- or extra-vascular) may be indicative of migration. Inadequate insertion and normal or underweight appear to increase the risk of migration. Scientific societies and authors offer practical strategies to deal with implant migration. CONCLUSION: Professionals who insert and remove contraceptive implants must be adequately trained. They need to be on the lookout for implant migration, and promptly refer patients to appropriate care if migration is suspected.
This systematic review documents and characterises 148 cases of vascular and extravascular etonogestrel contraceptive implant migration. Healthcare professionals must be aware of this rare but serious complication and be adequately trained to insert and remove contraceptive implants.
Subject(s)
Contraceptive Agents, Female , Desogestrel , Drug Implants , Foreign-Body Migration , Humans , Desogestrel/administration & dosage , Desogestrel/adverse effects , Female , Drug Implants/adverse effects , Contraceptive Agents, Female/administration & dosage , Contraceptive Agents, Female/adverse effects , Device Removal , Contraceptive Agents, Hormonal/adverse effects , Contraceptive Agents, Hormonal/administration & dosageABSTRACT
PURPOSE: This case report aims to report the development of cystoid macular edema (CME) unilaterally following the administration of bimatoprost implant (Durysta) injections in both eyes for the treatment of primary open-angle glaucoma (POAG). OBSERVATIONS: An 84-year-old female patient, previously diagnosed with POAG, underwent bimatoprost implant (Durysta) injections in both eyes, spaced one month apart. Subsequently, the patient experienced a gradual decline in visual acuity in her left eye attributed to the development of CME. The condition resolved following a treatment regimen involving topical dexamethasone and nepafenac. CONCLUSION: The use of bimatoprost implant may lead to the occurrence of CME. Ophthalmologists must vigilantly monitor patients post-implantation, especially if they exhibit visual symptoms or have risk factors for a CME.
Subject(s)
Antihypertensive Agents , Bimatoprost , Drug Implants , Glaucoma, Open-Angle , Intraocular Pressure , Macular Edema , Tomography, Optical Coherence , Visual Acuity , Humans , Macular Edema/diagnosis , Macular Edema/drug therapy , Female , Bimatoprost/adverse effects , Glaucoma, Open-Angle/drug therapy , Glaucoma, Open-Angle/surgery , Aged, 80 and over , Intraocular Pressure/drug effects , Drug Implants/adverse effects , Antihypertensive Agents/adverse effects , Glucocorticoids/administration & dosage , Glucocorticoids/adverse effects , Glucocorticoids/therapeutic use , Anterior Chamber , Dexamethasone/administration & dosage , Dexamethasone/adverse effectsSubject(s)
Dexamethasone , Drug Implants , Iatrogenic Disease , Retinal Hemorrhage , Humans , Male , Anti-Inflammatory Agents/administration & dosage , Anti-Inflammatory Agents/adverse effects , Dexamethasone/administration & dosage , Dexamethasone/adverse effects , Drug Implants/adverse effects , Intravitreal Injections/adverse effects , Retinal Hemorrhage/chemically induced , Retinal Hemorrhage/etiology , Retinal Hemorrhage/diagnosis , Aged, 80 and overABSTRACT
OBJECTIVE: Clinical factors related to development of amenorrhea in adolescents with the etonogestrel contraceptive implant are not well-understood. The purpose of this study is to describe what baseline clinical characteristics are associated with amenorrhea in adolescents with a contraceptive implant 12 months after placement. STUDY DESIGN: This retrospective cohort study included 252 post-menarchal individuals aged 12-22 years with a contraceptive implant placed between 2016-2020. Data abstracted at insertion, three months post-insertion, and 12 months post-insertion included demographics, baseline bleeding pattern, prior contraception use, post-insertion bleeding pattern, and method discontinuation. We assessed possible predictive characteristics of our outcomes using bivariate and multivariable logistic regression analyses. RESULTS: Twenty nine percent of patients were amenorrheic 12 months after placement. Patients who were amenorrheic at 12 months were more likely to be obese (41.1% vs 24.6%, p = 0.01), to have been amenorrheic prior to implant insertion (16.9% vs 5.4%, p < 0.01, to have used hormonal contraception immediately prior to insertion (42.5% vs 26.3%, p = 0.01), to have had the most recent contraceptive method being another implant (12.3% vs 3.6%, p = 0.02), and to have developed amenorrhea within three months after placement (22.2% vs 12.6%, p < 0.01). After multivariable regression analysis, only obesity (adjusted odds ratio [aOR] 2.2 95% CI 1.1-4.2) and amenorrhea at three months (aOR 3.6, CI 1.1-11.5) were associated with amenorrhea at 12 months. CONCLUSION: Obesity and early amenorrhea were associated with 12-month amenorrhea in adolescents using the etonogestrel subdermal implant. Understanding this can help with contraceptive method selection and counseling for patients and providers. IMPLICATIONS: Obesity and early amenorrhea with the etonogestrel contraceptive implant are associated with longer-term amenorrhea in adolescents using this method. These findings can aid providers with method selection and pre-insertion decision-making for adolescents considering contraceptive implant use, as well as continued counseling after placement.
Subject(s)
Contraceptive Agents, Female , Female , Humans , Adolescent , Contraceptive Agents, Female/adverse effects , Amenorrhea/chemically induced , Retrospective Studies , Desogestrel/adverse effects , Obesity , Drug Implants/adverse effectsABSTRACT
PURPOSE: to report a case of bilateral macular edema (ME) secondary to Rituximab infusions in a woman affected by IgG4-Related Disease and to review of prior cases of ME related to Rituximab. OBSERVATIONS: ME completely resolved after Intravitreal Dexamethasone Implant (IDI). CONCLUSIONS AND IMPORTANCE: ME is a rare complication after Rituximab infusions and very few cases are reported in the literature. Usually, ME occurs a few weeks after systemic administration and is probably related to a local release of cytokines. It resolves with oral, subtenon or intravitreal steroids. Our case is the first showing that IDI is a safe and effective treatment in ME secondary to Rituximab. Rituximab is not required to be discontinued if treatment for ME is started.
Subject(s)
Macular Edema , Retinal Vein Occlusion , Female , Humans , Dexamethasone , Macular Edema/diagnosis , Macular Edema/drug therapy , Rituximab/adverse effects , Intravitreal Injections , Drug Implants/adverse effects , Glucocorticoids/therapeutic use , Retinal Vein Occlusion/complicationsABSTRACT
BACKGROUND: Anterior Chamber bleeding without vitreous hemorrhage had been described after the removal of 23G vitrectomy cannulas. We report the case of an anterior chamber bleeding after an intravitreal Dexamethasone implant. CASE REPORT: One patient with macular edema due to central retinal vein occlusion in a vitrectomized eye underwent an intravitreal Dexamethasone implant. After the injection the patient suffered from anterior chamber bleeding without signs of vitreous hemorrhage. The complication resolved with a conservative treatment. CONCLUSION: Anterior Chamber bleeding is a possible complication of dexamethasone implant, that can be treated in a conservative way.
Subject(s)
Dexamethasone , Retinal Vein Occlusion , Humans , Dexamethasone/adverse effects , Glucocorticoids/adverse effects , Vitreous Hemorrhage/etiology , Vitreous Hemorrhage/complications , Drug Implants/adverse effects , Anterior Chamber , Retinal Vein Occlusion/complications , Retinal Vein Occlusion/diagnosis , Retinal Vein Occlusion/drug therapy , Intravitreal InjectionsABSTRACT
INTRODUCTION: Intravitreal dexamethasone (DEX) implant is indicated for the treatment of macular oedema due to diabetic retinopathy, retinal vein occlusion and uveitis. The most common complications are cataract and elevated intraocular pressure (IOP). Accidental injection of DEX implant into the lens is a rare complication and only few papers presented it. CASE PRESENTATION: A 40-year-old man was treated with DEX implant for diabetic macular oedema in both eyes. At 1 week follow-up visit, slit lamp examination showed the DEX implant was located in the crystalline lens of the right eye (RE) without any sign of inflammation, cataract or elevated IOP, so we decided to plan a normal follow-up schedule. Macular oedema relapsed 5 months after the injection in the left eye (LE), whereas the RE did not show any sing of intraretinal or subretinal fluid. Six months after DEX implantation an uneventful phacoemulsification and intraocular lens placement were performed in the RE because of IOP elevation. CONCLUSIONS: The therapeutic effect of DEX implant can be maintained for a longer period of time than intravitreal implant, determining complete reabsorption of macular oedema. Intralenticular implant can be maintained inside the lens until either IOP increases, cataract progresses, or other complications occur.
Subject(s)
Cataract , Diabetic Retinopathy , Macular Edema , Male , Humans , Adult , Dexamethasone , Glucocorticoids , Macular Edema/diagnosis , Macular Edema/drug therapy , Macular Edema/etiology , Follow-Up Studies , Intravitreal Injections , Cataract/chemically induced , Cataract/complications , Diabetic Retinopathy/complications , Diabetic Retinopathy/diagnosis , Diabetic Retinopathy/drug therapy , Drug Implants/adverse effects , Treatment OutcomeABSTRACT
OBJECTIVE: Implant-site necrosis is a rare complication. We present a case-series of a necrosis as an adverse effect after the etonogestrel (ENG)-subdermal contraceptive implant placement. MATERIAL AND METHODS: Five women with site necrosis after the ENG-implant placement and their clinical manifestations and treatments. RESULTS: Local pain was the main symptom, appearing within 35 days of placement. Outpatient multidisciplinary treatment was undertaken. Local debridement and implant removal was performed in four out of the five women. Time to complete healing varied from 45 days to 12 months. CONCLUSION: Early diagnosis and multidisciplinary treatment are essential to avoid severe aesthetic or functional damages and major life-threatening complications.
We presented five cases with necrosis at the ENG-implant site of placement in which we proposed an early diagnosis and multidisciplinary treatment to avoid severe aesthetic or functional damages.
Subject(s)
Contraceptive Agents, Female , Female , Humans , Contraceptive Agents, Female/adverse effects , Desogestrel/adverse effects , Device Removal , Drug Implants/adverse effectsSubject(s)
Glaucoma , Retinal Diseases , Retinal Vein Occlusion , Humans , Glaucoma/complications , Dexamethasone/adverse effects , Retinal Diseases/complications , Intravitreal Injections , Drug Implants/adverse effects , Glucocorticoids/adverse effects , Retinal Vein Occlusion/complications , Treatment OutcomeABSTRACT
These guidelines are a consensus of French glaucoma and retina experts on the management of ocular hypertension (OHT) observed in a third of the cases after corticosteroid implant intravitreal injections. They update the first guidelines published in 2017. Two implants are marketed in France: the dexamethasone implant (DEXi) and the fluocinolone acetonide implant (FAci). It is essential to assess the pressure status before injecting a patient with a corticosteroid implant. A molecule-specific monitoring of the intraocular pressure is needed throughout the follow-up and at the time of reinjections. Real-life studies have allowed optimizing the management algorithm by significantly increasing the safety of these implants. Corticosteroid testing with DEXi should be performed before switching to FAci to optimize pressure tolerance of FAci. Beyond topical hypotensive treatments, selective laser trabeculoplasty may be considered in the therapeutic arsenal for the management of steroid-induced OHT and subsequent injections.
Subject(s)
Glaucoma , Ocular Hypertension , Ophthalmology , Humans , Dexamethasone , Ocular Hypertension/chemically induced , Glaucoma/drug therapy , Glucocorticoids/therapeutic use , Intraocular Pressure , Adrenal Cortex Hormones/adverse effects , Intravitreal Injections , Steroids/therapeutic use , Retina , Drug Implants/adverse effectsABSTRACT
We present a patient who experienced an unintended pregnancy after transitioning from the copper intrauterine device to the etonogestrel subdermal implant. When switching from contraceptive methods that do not reliably suppress ovulation, clinicians should consider backup contraception and additional counseling, depending on the specific timing of removal.
Subject(s)
Contraceptive Agents, Female , Intrauterine Devices, Copper , Pregnancy , Female , Humans , Pregnancy, Unplanned , Intrauterine Devices, Copper/adverse effects , Drug Implants/adverse effects , ContraceptionSubject(s)
Dexamethasone , Glucocorticoids , Humans , Male , Adult , Dexamethasone/adverse effects , Injections , Drug Implants/adverse effects , Intravitreal InjectionsABSTRACT
Patients rarely experience complications at the time of Etonogestrel subdermal contraceptive implant placement. Few case reports describe infection or allergy as a complication at the time of implant insertion. In this case series, we discuss three infections and one allergic reaction following Etonogestrel implant placement, review six previous case reports of eight cases of infection or allergy, and discuss management of these complications. We highlight differential diagnosis when encountering a placement complication, considerations of dermatologic conditions when placing Etonogestrel implants, and discuss when to consider removal of the implant when a complication occurs.
Subject(s)
Contraceptive Agents, Female , Hypersensitivity , Female , Humans , Contraceptive Agents, Female/adverse effects , Desogestrel/adverse effects , Device Removal , Drug Implants/adverse effectsABSTRACT
PURPOSE: To describe cases of visually significant vitreous hemorrhage (VH) following dexamethasone intravitreal implant in our practice and present two cases that required surgical intervention and a case of VH and hypotony following dexamethasone implant. An injection technique that may minimize the incidence of these complications is described and illustrated. METHODS: Retrospective case series. RESULTS: The overall incidence of VH was 1.7% (8 of 467 injections) and those that required surgical intervention was 0.4% (2/467) over a 10-year period, from June 2010 to June 2020 ( Table 1 ). Overall, 75% (6 of 8) VH resolved spontaneously over time, without surgical intervention. CONCLUSION: Nonclearing VH and hypotony are rare but serious complications of dexamethasone implant.
Subject(s)
Glucocorticoids , Macular Edema , Humans , Glucocorticoids/adverse effects , Dexamethasone/adverse effects , Vitreous Hemorrhage/chemically induced , Vitreous Hemorrhage/complications , Retrospective Studies , Macular Edema/drug therapy , Macular Edema/etiology , Drug Implants/adverse effects , Intravitreal InjectionsABSTRACT
PURPOSE: Our study aimed to evaluate the acceptability, adverse effects and continuation rates among adolescents who accepted the etonogestrel (ENG) subdermal implant and compared to adolescents who chose other methods during the immediate postpartum period before hospital discharge, with one year follow-up up. MATERIALS AND METHODS: We conducted a cohort non-randomised study at the Women's Hospital, University of Campinas. All women up to 19 years of age, who gave birth at the hospital between July 2019 and April 2020, were invited to participate and were offered the ENG-implant or the routine contraceptive methods. They were followed for one year postpartum. RESULTS: We included 100 teenagers and 72 accepted the ENG-implant. Students are more likely to accept the ENG-implant than non-students (PR: 1.25 [95%CI 0.99-1.59]). Up to one year of follow-up, survival analysis showed that the time of adherence to the method was longer for the ENG-implant users (p = 0.0049). More than 90% of the adolescents were satisfied with the implant; however, five requested early removal due to menstrual irregularity and local discomfort. CONCLUSION: Provision ENG-implant for adolescents in the immediate postpartum demonstrated high acceptance and ensured effective contraception. After one year, most of them were satisfied, with a high continuation rate and without unplanned pregnancies.